This post is from a suggested group
The European Society of Medicine published NDR's opinion piece Amyotrophic Lateral Sclerosis is a spectrum of diseases that needs a broad treatment approach. The editorial is support for our position that thymopentin in the form of FC-12738 can bring a major contribution to the ALS field because it is designed to regulate the cell danger response by natural innate immune pathways. It was Richards hope to bring such a treatment to those diagnosed with ALS. The human trial (in normal subjects) wrapped up with no issues. When the paperwork completes we will move into ALS patients. Richard would be pleased.
Last year, my 68-year-old partner was diagnosed with Lou Gehrig's disease also known as ALS. Speaking and swallowing were two of his challenges. His collapse was swift and catastrophic, and neither the riluzole nor the medical staff did much to aid him. He would not have survived if our primary care physician hadn't given him attentive care and attention, as the hospital center didn't provide any psychological support. His fall was abrupt and catastrophic. His hands and legs gave way to weakness in his arms. This year our family physician suggested using vinehealthcentre. com ALS/MND treatment, which my husband has been receiving for a few months now. I'm delighted to say that the treatment greatly reduced and reversed his symptoms of ALS, he no longer requires a feeding tube, sleeps soundly, works out frequently, and is now very active. In the hopes that it could be useful, I thought I would relate my husband's tale; in the end, you have to do what suits you the best.